Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...